Show simple item record

dc.contributor.authorEdmonds, Sterling
dc.contributor.authorMacGregor, Andrea
dc.contributor.authorDoll, Agnieszka
dc.contributor.authorVural, Ipek Eren
dc.contributor.authorGraham, Janice
dc.contributor.authorFierlbeck, Katherine
dc.contributor.authorLexchin, Joel
dc.contributor.authorDoshi, Peter
dc.contributor.authorHerder, Matthew
dc.date.accessioned2021-02-11T15:53:00Z
dc.date.available2021-02-11T15:53:00Z
dc.date.issued2020-11-19
dc.identifier.urihttp://hdl.handle.net/10713/14655
dc.description.urihttps://doi.org/10.1093/jlb/lsaa083en_US
dc.language.isoenen_US
dc.publisherOxford University Pressen_US
dc.relation.ispartofJournal of Law and the Biosciencesen_US
dc.subjectCOVID-19en_US
dc.subjectpandemicen_US
dc.subjectpharmaceutical regulationen_US
dc.subjecttransparencyen_US
dc.subjectvaccines and drugsen_US
dc.titleTransparency too little, too late? Why and how Health Canada should make clinical data and regulatory decision-making open to scrutiny in the face of COVID-19en_US
dc.typeArticleen_US
dc.identifier.doi10.1093/jlb/lsaa083
dc.identifier.pmid33537149
dc.source.volume7
dc.source.issue1
dc.source.beginpagelsaa083
dc.source.endpage
dc.source.countryEngland


This item appears in the following Collection(s)

Show simple item record